41 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents.
Northern Illinois University
Synthesis and antitumor activity of 1,3,4-oxadiazole possessing 1,4-benzodioxan moiety as a novel class of potent methionine aminopeptidase type II inhibitors.
Nanjing University
Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells.
Johns Hopkins University School of Medicine
QSAR study of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2 using LS-SVM and GRNN based on principal components.
Kermanshah University of Medical Sciences
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
Universit£T Heidelberg
A selective account of effective paradigms and significant outcomes in the discovery of inspirational marine natural products.
University of California Santa Cruz
Synthesis and antitumor activity of 1,2,4-triazoles having 1,4-benzodioxan fragment as a novel class of potent methionine aminopeptidase type II inhibitors.
Nanjing University
Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo.
The Johns Hopkins University School of Medicine
Novel Antimicrobial 8-Hydroxyquinoline-Based Agents: Current Development, Structure-Activity Relationships, and Perspectives.
Universidade Federal Do Rio Grande Do Sul
Design and synthesis of beta-amino-alpha-hydroxy amide derivatives as inhibitors of MetAP2 and HUVEC growth.
Celera
3-Amino-2-hydroxyamides and related compounds as inhibitors of methionine aminopeptidase-2.
Abbott Laboratories
Peptidyl hydroxamic acids as methionine aminopeptidase inhibitors.
The Ohio State University
Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis.
Johns Hopkins University School of Medicine
Structure-based optimisation of orally active & reversible MetAP-2 inhibitors maintaining a tight 'molecular budget'.
Glaxosmithkline
Discovery and Structure-Based Optimization of Next-Generation Reversible Methionine Aminopeptidase-2 (MetAP-2) Inhibitors.
Merck Healthcare
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
Eberhard Karls University T£Bingen
Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives.
Northwest University
The Bengamides: A Mini-Review of Natural Sources, Analogues, Biological Properties, Biosynthetic Origins, and Future Prospects.
Colorado Mesa University
Substituted 2-hydroxy-4-(2-(phenylsulfonamido)acetamido)benzoic acid analogs as inhibitors of STAT protein
The Governing Council of The University of Toronto
Substituted pyrrolidines as factor XIa inhibitors for the treatment thromboembolic diseases
Ono Pharmaceutical
Heterocyclic GSK-3 allosteric modulators
Consejo Superior de Investigaciones Cientificas (CSIC)
Substituted tetrahydrocarbazole and carbazole carboxamide compounds
Bristol-Myers Squibb
Fused pyrimidine compound, and preparation method, intermediate, composition, and uses thereof
Shanghai Yingli Pharmaceutical
5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds, compositions and methods of use thereof
Genentech
Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
Emory University
Characterisation and comparison of novel ligands for the nociceptin/orphanin FQ receptor.
Leicester Royal Infirmary
Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitors with potent and selective activity against the malaria parasite Plasmodium falciparum.
University of Texas At Dallas
Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine a.
University of British Columbia
Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase.
Merck Frosst Center For Therapeutic Research
A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.
Banyu Tsukuba Research Institute